Spondyloarthritis   

How do you view it relative to existing options like TNFi, IL-23, or IL-17s like ixekizumab?

For example, in patients with many swollen/tender joints, enthesitis, nail involvement do you expect particularly good response? Are there patients in...

How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections see in the BE COMPLE...

The patient has no extraocular features of a spondyloarthropathy and is on methotrexate. No active eye disease for past 1 year.

IgG4 manifestations include autoimmune pancreatitis and periaortic soft tissue mass.

Is an MRI necessary to diagnose non-radiographic axial spondyloarthritis?

Is there a certain disease duration or age beyond which you taper immunosuppressive treatments?

In what cases do you discontinue the medication?

Patient with sacroiliitis on imaging, failure of two NSAIDs.

Are there ways to overcome barriers in insurance coverage of this combination of treatments?

Is there a role for immunosuppressive medications such as TNF inhibitors in the management of IgA nephropathy in this setting?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

There is some emerging evidence that there is an inflammatory component. 

Are IL-17 or IL-23 inhibitors helpful?

Can axSpA affect the spine without affecting the sacroiliac joints?

In patients refractory to NSAIDs and sulfasalazine